High prevalent early damage independently predicts future mortality in an inception cohort of Takayasu arteritis
- 25 September 2025
- journal article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (1)
Abstract
Objectives: The objective of this study was to evaluate early damage, and its evolution and prognostic relevance in an inception cohort of patients with Takayasu arteritis (TAK) using the Large Vessel Vasculitis Index of Damage (LVVID). Methods: Baseline LVVID was scored in an inception cohort of TAK who were within 3 months of cohort entry, at 1 year, and at the last follow-up at or after 1 year. Levels of associations between initial LVVID scores and demographic characteristics, disease activity, and angiographic subtypes were evaluated. Hazard ratios (HRs) for mortality per point/quartile increase in baseline LVVID scores were calculated using Cox proportional hazards regression. Damage evolution from baseline to 1 year or last follow-up was assessed using the paired Student’s t test. Pre-treatment predictors of progression were assessed using logistic regression. Results: Of 199 patients (141 females; 54 paediatric-onset), 192/199 (96.5%) had damage (most often cardiovascular) as indicated by the LVVID at presentation, 112/114 (98.2%) at 1 year, and 126/130 (96.9%) at last follow-up. Initial LVVID was greater with active disease, Hata’s type V, or Goel’s cluster 1 angiographic subtypes. Higher baseline LVVID was consistently associated with increased mortality [crude HR per point increase 1.49 (95% CI 1.24–1.81) or per quartile increase in LVVID 1.92 (1.21–3.05)], despite adjustment for disease activity or angiographic subtype. Significant progression of LVVID was observed at 1 year (3.49 ± 2.01 vs 3.27 ± 1.86, P < 0.001) or at the last follow-up (3.73 ± 2.18 vs 3.28 ± 1.88 P < 0.001), and was predicted by active disease at presentation [ odds ratio (OR) 2.89] and glucocorticoid (OR 3.53) or immunosuppressant use (OR 3.52). Conclusion: Most patients with TAK had recordable early damage, which was associated with future mortality.Keywords
This publication has 38 references indexed in Scilit:
- Current evidence on the role of fibroblasts in large-vessel vasculitides: From pathogenesis to therapeuticsAutoimmunity Reviews, 2024
- Renal artery involvement is associated with increased morbidity but not mortality in Takayasu arteritis: a matched cohort study of 215 patientsClinical Rheumatology, 2023
- Management of Takayasu arteritisBest Practice & Research Clinical Rheumatology, 2023
- The effectiveness of tocilizumab and its comparison with tumor necrosis factor alpha inhibitors for Takayasu Arteritis: A systematic review and meta-analysisAutoimmunity Reviews, 2023
- Core concepts in pharmacoepidemiology: Confounding by indication and the role of active comparatorsPharmacoepidemiology and Drug Safety, 2022
- Corticosteroid monotherapy for the management of Takayasu arteritis—a systematic review and meta-analysisRheumatology International, 2021
- Disease-modifying anti-rheumatic drugs for the management of Takayasu arteritis—a systematic review and meta-analysisClinical Rheumatology, 2021
- Damage Assessment in ANCA-Associated VasculitisCurrent Rheumatology Reports, 2012
- Development and initial validation of the vasculitis damage index for the standardized clinical assessment of damage in the systemic vasculitidesArthritis & Rheumatism, 1997
- The American College of Rheumatology 1990 criteria for the classification of takayasu arteritisArthritis & Rheumatism, 1990